{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:22:33Z","timestamp":1771561353291,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1245\/s10434-024-15763-2","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T17:01:29Z","timestamp":1720285289000},"page":"5475-5478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Finally! An Improved Prognostic Calculator for Cutaneous Melanoma"],"prefix":"10.1245","volume":"31","author":[{"given":"Michael E.","family":"Egger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly M.","family":"McMasters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"key":"15763_CR1","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1200\/JCO.19.02362","volume":"38","author":"SN Lo","year":"2020","unstructured":"Lo SN, Ma J, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Australia nomogram. J Clin Oncol. 2020;38:2719\u201327.","journal-title":"J Clin Oncol."},{"key":"15763_CR2","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.23.01020","volume":"42","author":"AHR Varey","year":"2024","unstructured":"Varey AHR, Li I, El Sharouni MA, et al. Predicting recurrence-free and overall survival for patients with stage II melanoma: the MIA calculator. J Clin Oncol. 2024;42:1169\u201380.","journal-title":"J Clin Oncol."},{"key":"15763_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/bjs.10995","volume":"106","author":"D Verver","year":"2019","unstructured":"Verver D, van Klaveren D, Franke V, et al. Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes. Br J Surg. 2019;106:217\u201325.","journal-title":"Br J Surg."},{"key":"15763_CR4","doi-asserted-by":"publisher","first-page":"106974","DOI":"10.1016\/j.ejso.2023.06.026","volume":"49","author":"J Lyth","year":"2023","unstructured":"Lyth J, Mikiver R, Nielsen K, Ingvar C, Olofsson Bagge R, Isaksson K. Population-based prognostic instrument (SweMR 2.0) for melanoma-specific survival: an ideal tool for individualised treatment decisions for Swedish patients. Eur J Surg Oncol. 2023;49:106974.","journal-title":"Eur J Surg Oncol."},{"key":"15763_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jamcollsurg.2011.12.027","volume":"214","author":"GG Callender","year":"2012","unstructured":"Callender GG, Gershenwald JE, Egger ME, et al. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg. 2012;214:608\u201317.","journal-title":"J Am Coll Surg."},{"key":"15763_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med."},{"key":"15763_CR7","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801.","journal-title":"N Engl J Med."},{"key":"15763_CR8","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med."},{"key":"15763_CR9","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718\u201329.","journal-title":"Lancet."},{"key":"15763_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(24)00076-7","volume":"25","author":"RC Stassen","year":"2024","unstructured":"Stassen RC, Maas C, van der Veldt AAM, et al. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis. Lancet Oncol. 2024;25:509\u201317.","journal-title":"Lancet Oncol."},{"key":"15763_CR11","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211\u201322.","journal-title":"N Engl J Med."},{"key":"15763_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jamcollsurg.2018.12.030","volume":"228","author":"ME Egger","year":"2019","unstructured":"Egger ME, Stevenson M, Bhutiani N, et al. Should sentinel lymph node biopsy be performed for all T1b melanomas in the new 8(th) edition American Joint Committee on Cancer staging system? J Am Coll Surg. 2019;228:466\u201372.","journal-title":"J Am Coll Surg."},{"key":"15763_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","volume":"18","author":"JS Zager","year":"2018","unstructured":"Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18:130.","journal-title":"BMC Cancer."},{"key":"15763_CR14","first-page":"PO.20.00119","volume":"5","author":"EC Hsueh","year":"2021","unstructured":"Hsueh EC, DeBloom JR, Lee JH, et al. Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma. JCO Precis Oncol. 2021;5.PO.20.00119","journal-title":"JCO Precis Oncol."},{"key":"15763_CR15","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/cam4.2128","volume":"8","author":"J Keller","year":"2019","unstructured":"Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med. 2019;8:2205\u201312.","journal-title":"Cancer Med."},{"key":"15763_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2020.08.029","volume":"140","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Bellomo D, Arias-Mejias SM, et al. Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. Eur J Cancer. 2020;140:11\u20138.","journal-title":"Eur J Cancer."},{"key":"15763_CR17","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.3390\/cancers14122854","volume":"14","author":"E Mulder","year":"2022","unstructured":"Mulder E, Johansson I, Gr\u00fcnhagen DJ, et al. Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I-II melanoma patients at risk of disease relapse. Cancers Basel. 2022;14:2854","journal-title":"Cancers Basel."},{"key":"15763_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2022.12.021","volume":"182","author":"T Amaral","year":"2023","unstructured":"Amaral T, Sinnberg T, Chatziioannou E, et al. Identification of stage I\/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Eur J Cancer. 2023;182:155\u201362.","journal-title":"Eur J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15763-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T18:27:33Z","timestamp":1722882453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15763-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["15763"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15763-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,6]]},"assertion":[{"value":"3 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael E. Egger reports a consultancy agreement with Iovance Biotherapeutics and institutional research support for a sponsored clinical trial from SkylineDx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}